COMP <GO>
GMAB vs UNH // EV/EBITDA & P/E VALUATION
Genmab A/S ADS (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: GMAB 7
— UNH 6
▲ EV/EBITDA & P/E VALUATION LEADER: UNH
LAST: $57.06 (+1.01%) • MKT CAP: $35.61B
valuation
21.0x
LAST: $406.97 (-0.96%) • MKT CAP: $365.29B
valuation
16.5x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GMAB VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GMAB | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 88.57% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 11.47% | -1.57 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 21.0x | 16.5x | +4.52 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 6.47% | -4.26 | UNH | /fcf-yield <GO> |
| Operating Margin | 13.90% | 4.82% | +9.08 | GMAB | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 3.14% | +7.76 | GMAB | /net-margins <GO> |
| Revenue Growth (YoY) | 22.00% | 6.46% | +15.54 | GMAB | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.32% | -2.32 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 3.12 | +0.62 | GMAB | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GMAB | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.11% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 85.6 | 57.4 | +28.20 | GMAB | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.09 | 0.33 | +0.76 | GMAB | /macro-sensitivity <GO> |
| Forward P/E Multiple | 27.6x | 17.7x | +9.86 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $35.61B | $365.29B | -$329.69B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GMAB REV | UNH REV | GMAB GROSS % | UNH GROSS % | GMAB FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | — | $447.57B | — | 88.7% | — | $16.07B |
| FY 2024 | — | $400.28B | — | 88.3% | — | $20.70B |
| FY 2023 | — | $371.62B | — | 89.6% | — | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GMAB // BETA 1.09
UNH // BETA 0.33